A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
- 14 May 2015
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (10) , 2201-2203
Abstract
HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy. Clin Cancer Res; 21(10); 2201–3. ©2015 AACR. See related article by Janakiram et al., p. 2359Keywords
This publication has 10 references indexed in Scilit:
- A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2Clinical Cancer Research, 2015
- Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinClinical Cancer Research, 2015
- Biofunctions of three new B7 family members (IRM7P.486)The Journal of Immunology, 2014
- B7-H5 costimulates human T cells via CD28HNature Communications, 2013
- HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionProceedings of the National Academy of Sciences, 2013
- Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesisMolecular Biology of the Cell, 2012
- Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHCImmunogenetics, 2012
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretionNature Medicine, 1999
- Endogenous Retroviruses Provide the Primary Polyadenylation Signal for Two New Human Genes (HHLA2 and HHLA3)Genomics, 1999